SMAD3 and cancer: miRNA-491 has been evaluated mostly in cancer, but it has been shown that target mRNAs involved in strong profibrotic pathways including TGF-β/SMAD3/NF-κB and Wnt3a/β-catenin signaling pathways [36,37].